StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research note issued to investors on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Down 25.5 %
Shares of BLPH opened at $0.01 on Friday. The firm has a fifty day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. Bellerophon Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.02. The stock has a market capitalization of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74.
Bellerophon Therapeutics Announces Dividend
The firm also recently declared a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were issued a dividend of $0.019 per share. The ex-dividend date was Thursday, December 19th. This represents a yield of 117.8%.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- 3 Monster Growth Stocks to Buy Now
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- The Role Economic Reports Play in a Successful Investment Strategy
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
